Novo Nordisk seeks acquisition deal to strengthen obesity product portfolio
Novo Nordisk CEO Maziar Mike Doustdar stated on January 13 local time that the company is seeking acquisition deals to strengthen its obesity product portfolio, "regardless of size." Doustdar said, "As long as it complements our own assets, we can pursue large-scale acquisitions, but it must be value-driven." (Jiemian)
Source: 36Kr The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments